In addition, U2AF1 mutations may not affect the response rate or survival of MDS patients who are treated with first-line hypomethylation or decitabine therapies, suggesting that U2AF1mut patients can also benefit from these treatments [33,53]. Here, U2AF1 is linked to myelodysplastic syndrome.